These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

968 related items for PubMed ID: 19936751

  • 1. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB.
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M, Schønnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P.
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D, Miner T, Akerman P, Millis R, Jean M, Kennedy T, Safran H.
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [Abstract] [Full Text] [Related]

  • 7. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K, Xenidis N, Chelis L, Chiotis A, Tentes A, Chatzaki E, Kortsaris A, Polychronidis A, Karakitsos P, Kakolyris S.
    Acta Oncol; 2010 Aug; 49(2):245-51. PubMed ID: 19839918
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP.
    Chemotherapy; 2012 Sep; 58(1):1-7. PubMed ID: 22310723
    [Abstract] [Full Text] [Related]

  • 11. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Liu C, Sun Q, Hang X, Zhong B, Wang D.
    Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
    Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):623-9. PubMed ID: 17522863
    [Abstract] [Full Text] [Related]

  • 14. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, Mavroudis D, Xenidis N, Georgoulias V.
    Oncology; 2004 Apr; 66(4):253-9. PubMed ID: 15218291
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ.
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
    Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS, Kang YK.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
    Kim JG, Sohn SK, Kim DH, Baek JH, Sung WJ, Park JY, Kim TB, Jung HY, Yu W, Lee KB.
    Oncology; 2005 Apr; 68(2-3):190-5. PubMed ID: 16006756
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK.
    Oncology; 2010 Apr; 78(2):125-9. PubMed ID: 20389134
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.